In type 2 diabetes, glucose phosphorylation, a regulatory step in glucose utilization by skeletal muscle, is impaired. Since glucokinase expression in skeletal muscle of transgenic mice increases glucose phosphorylation, we examined whether such mice counteract the obesity and insulin resistance induced by 12 wk of a high-fat diet. When fed this diet, control mice became obese, whereas transgenic mice remained lean. Furthermore, high-fat fed control mice developed hyperglycemia and hyperinsulinemia (a 3-fold increase), indicating that they were insulin resistant. In contrast, transgenic mice were normoglycemic and showed only a mild increase in insulinemia (1.5-fold). They also showed improved whole body glucose tolerance and insulin sensitivity and increased intramuscular concentrations of glucose 6-phosphate and glycogen. A parallel increase in uncoupling protein 3 mRNA levels in skeletal muscle of glucokinaseexpressing transgenic mice was also observed. These results suggest that the rise in glucose phosphorylation by glucokinase expression in skeletal muscle leads to increased glucose utilization and energy expenditure that counteracts weight gain and maintains insulin sensitivity.
. In type 2 diabetic patients, glucose transport in skeletal muscle in response to euglycemic hyperinsulinemia is impaired. However, glucose phosphorylation is impaired to an even greater extent, and as a result the intracellular free glucose concentration increases (13) . This indicates that, although both glucose transport and phosphorylation are resistant to the action of insulin, impaired glucose phosphorylation is probably the rate-limiting step for insulin action (13) . Furthermore, reduced hexokinase II and low basal levels of glucose 6-phosphate in skeletal muscle and adipose tissue have been found in type 2 diabetic patients (16) (17) . In an attempt to increase skeletal muscle glucose phosphorylation and to avoid the feedback inhibition of hexokinase activity by glucose 6-phosphate, the liver enzyme glucokinase (GK) was expressed in skeletal muscle of transgenic mice (18) . This resulted in increased glucose uptake and utilization by skeletal muscle and increased glucose disposal after an intraperitoneal glucose load (18) . Similar results were obtained after adenovirus-mediated GK gene transfer to skeletal muscle of rats (19) . Furthermore, GK expression in the skeletal muscle reduces type 1 diabetic hyperglycemia in transgenic mice (18) . However, although GK expression in skeletal muscle of diabetic Zucker fatty rats improved insulin-sensitive glucose uptake, it did not prevent hyperglycemia and the obesity induced by the lack of leptin receptor in the Zucker rat (20) .
The aim of this study was to determine whether increased glucose phosphorylation in transgenic mice expressing GK in skeletal muscle reduces the obesity and insulin resistance induced by a high-fat diet. We found that control mice became obese and insulin resistant, whereas transgenic mice remained lean, glucose tolerant, and insulin sensitive.
MATERIALS AND METHODS

Treatment of mice
Transgenic mice expressing the GK gene in skeletal muscle under the control of the myosin-light chain 1 promoter/enhancer (MLC/GK), which expressed high levels of GK in skeletal muscle, were used (18) . To obtain the MLC/GK chimeric gene, a 2.3 kb EcoRI-EcoRI fragment containing the entire coding sequence and the polyadenylation signal of the rat liver GK cDNA (from Dr. P. Iynedjian, University of Geneva, Geneva, Switzerland) was used. This fragment was introduced in an EcoRI site in the pMDAF2 vector, which contains a 1.5 kb fragment of the MLC1 promoter and 0.9 kb fragment of the MLC1/3 gene, muscle-specific enhancer (21, 22) . The 1.5 kb fragment of the MLC1 promoter and 0.9 kb fragment of the MLC1/3 gene, musclespecific enhancer used in this study direct the expression of foreign genes specifically to skeletal muscle (selective expression in fast-twitch muscle fibers) in a rostrocaudal gradient (21) (22) (23) . The final plasmid was designated pMLC/GK. Two lines of transgenic mice [MLC/GK1 (Tg1) and MLC/GK7 (Tg2)] were examined. Nontransgenic littermates were used as controls for the transgenic animals. All mice used in this study were of a C57BL/6;SJL mixed background. Mice were fed ad libitum with a standard diet (9% of calories from fat; Panlab, A04, Barcelona, Spain) and maintained under a light-dark cycle of 12 h (lights on at 8:00 AM). For the experimental induction of type 2 diabetes, mice were kept in individual cages and fed a high-fat diet (42% of calories from fat; Teklad, TD 88137) for up to 12 wk. Where stated, mice were fasted for 15 h. Animals were killed, and samples (quadriceps and gastrocnemius muscles and liver) were taken between 9-11 AM. In the experiments described below, heterozygous male mice aged 8 wk at the start of the diet were used. All experimental procedures involving mice were approved by the Ethics in Human and Animal Experimentation Committee of the Universitat Autònoma de Barcelona.
RNA analysis
Total RNA was obtained from skeletal muscle or liver by the guanidine isothiocyanate method (24) , and RNA samples (30 µg) were electrophoresed on a 1% agarose gel containing 2.2 M formaldehyde. Northern blots were hybridized to the following 32 P-labeled probes: a 2.3 kb EcoRI-EcoRI fragment corresponding to the rat GK cDNA; uncoupling protein 3 (UCP3), a 1 kb EcoRV-EcoRV fragment of human UCP3 cDNA; and a 1.3 kb EcoRI-EcoRI fragment corresponding to the rabbit ß-actin cDNA. These probes were labeled with [α-32 P]dCTP, following the method of random oligopriming as described by the manufacturer (Roche Applied Science). Specific activity of the DNA probe thus labeled was approximately 10 9 cpm/µg DNA. Membranes were placed in contact with Kodak XAR-5 films. The ß-actin signal was used to correct for loading inequalities. Densitometric analysis of autoradiograms was performed at nonsaturating exposures with a scanning densitometer (Fujix, BAS 1000).
Western blot analysis
Western blot analysis of GK expression was performed by standard procedures from total cellular homogenates of skeletal muscle and liver (25) . Tissues were homogenized in a buffer containing 100 mM glucose, 100 mM KCl, 50 mM triethanolamine, 1 mM DTT, 5% (v/v) glycerol, 5 mM EDTA, 5 mM EGTA, 50 µM phenylmethylsulfonyl fluoride (PMSF), 25 ng/ml leupeptin, and 0.02% NaN 3 . Samples were centrifuged, and an aliquot of the supernatant was assayed for protein concentration using the Bradford method as described by the manufacturer (Bio-Rad protein assay). Ten micrograms of protein were electrophoresed on 10% SDS-PAGE and transferred to nitrocellulose membranes. To detect GK a sheep polyclonal antibody to rat GK (a gift from Dr. M. Magnuson, Vanderbilt University, Nashville, TN,) diluted 1:1000 was used.
Metabolite assays
To determine the concentration of metabolites, skeletal muscle samples were clamp frozen in situ and kept at -80C until analysis. The concentrations of glycogen and glucose 6-phosphate were measured in perchloric extracts, which were adjusted to pH 5 with 5 M K 2 CO 3 to determine glycogen and to pH 7 for glucose 6-phosphate. Glycogen levels were measured using the α-amyloglucosidase method (26) . Glucose 6-phosphate was determined enzymatically (27) . Glucose was determined in blood by using a Glucometer Elite® (Bayer, Germany) following the instructions of the manufacturer. Lactate was measured by the lactate dehydrogenase method (28) . Insulin was measured in serum by radioimmunoassay (CIS, Biointernational, Gif-SurYvette, France).
Glucose and insulin tolerance tests
For glucose tolerance test, control and transgenic mice fasted overnight (16 h) with free access to water were given an intraperitoneal injection of glucose (0.5 g/kg body wt). For intraperitoneal insulin tolerance test, awake fed control and transgenic mice were intraperitoneally injected with 0.75 IU/kg body wt of an insulin solution (Humulin regular, Eli Lilly). Glucose concentration was determined in blood samples obtained from tail vein before and at the indicated time points after the glucose or insulin injection, respectively.
Statistical analysis
Results are means ± SE. The statistical significance of differences between data were analyzed using the Student t test. Differences were considered statistically significant at P < 0.05.
RESULTS
Counteraction of high-fat diet induced obesity by GK expression in skeletal muscle
Transgenic mice expressing the GK gene in skeletal muscle show improved glucose disposal and whole body glucose tolerance (18) . To determine whether the diabetogenic effect of a high-fat diet is counteracted by the expression of GK in skeletal muscle, control littermates and transgenic mice from lines Tg1 and Tg2 were fed this diet for 12 wk. At the end of this period, control mice had gained ~60% of body weight and were obese (from 28.0±0.6 to 45.3±0.9 g; Fig. 1 ), whereas transgenic mice showed only a 35% increase (from 26.0±0.8 to 35.1±0.9 g for Tg1 and from 26.2±0.7 to 35.5±0.8 g for Tg2; Fig. 1 ). Nevertheless, control and transgenic mice fed a standard diet had a similar increase in body weight (25 and 22%, respectively; from 28.0±0.3 to 35.2±0.8 g for controls, from 26.0±0.8 to 31.6±0.6 g for Tg1, and from 25.7±0.4 to 31.7±0.9 g for Tg2). Both control and transgenic mice had similar food intake (4.5±0.4 g/day of standard diet and 4.0±0.4 g/day of high-fat diet).
Prevention of glucose intolerance and insulin resistance by GK expression in skeletal muscle
After being fed a high-fat diet control mice were hyperglycemic, both when fed or after an overnight fast ( Fig. 2A and B) , and hyperinsulinemic (~3-fold increase; Fig. 2C ). In contrast, transgenic mice fed a high-fat diet remained normoglycemic ( Fig. 2A and B ) and showed only a mild increase in insulinemia (~1.5-fold; Fig. 2C ). When an intraperitoneal glucose tolerance test was performed after 12 wk on a high-fat diet, blood glucose levels in the transgenic group were lower than in high-fat fed controls and quite similar to control mice fed a standard diet (Fig. 3A) . This indicated that the transgenic mice maintained whole body glucose tolerance. Moreover, during an intraperitoneal insulin tolerance test performed after 12 wk on a high-fat diet, a significantly increased hypoglycemic response was observed in transgenic mice compared with control mice (Fig. 3B) . Thus, by 60 min after insulin injection, transgenic mice fed a high-fat diet showed a 55% decrease in blood glucose levels, whereas control mice fed a high-fat diet had only a 25% reduction in glycemia. This indicated that transgenic mice were more sensitive to the hypoglycemic effects of insulin. Thus, all these results show that after a high-fat diet, whereas control mice developed insulin resistance, transgenic mice expressing GK in the skeletal muscle showed improved glucose tolerance and were normoglycemic and insulin sensitive.
Effect of GK expression on skeletal muscle glucose metabolism
After 12 wk on a high-fat diet, skeletal muscle of Tg1 and Tg2 mice had similar levels of GK protein to those fed a standard diet (Fig. 4A) . No expression of the transgene was detected in the white or brown adipose tissue, heart, spleen, or brain of the transgenic mice (data not shown). The presence of GK increased (~2-fold) the intracellular concentration of glucose 6-phosphate in skeletal muscle of Tg1 and Tg2 (Fig. 4B ). This increase in glucose phosphorylation was parallel to a rise in glycogen content (~50%) in both transgenic lines (Fig. 4C) . Furthermore, control mice fed a high-fat diet showed lower serum lactate levels than control mice fed a standard diet (3.7±0.8 vs. 5.0±1 mM, respectively). In contrast, high-fat fed transgenic mice showed normal serum concentration of lactate (5.0±1 mM Tg1 and 5.4±0.4 mM Tg2), probably resulting from the induction of glycolytic flux in skeletal muscle expressing GK.
UCP3 overexpression was induced in skeletal muscle of transgenic mice expressing GK
The lower body weight increase, together with the same food intake as the controls, observed in the transgenic mice suggested an increase in energy expenditure by the skeletal muscle of these animals. Thus, the expression of UCP3 was determined in skeletal muscle of control and transgenic mice fed a high-fat diet for 12 wk. An increase (~2-fold) in the UCP3 mRNA levels was detected in high-fat fed transgenic mice (Fig. 5) . Furthermore, an increase (~1.5 fold) was also detected in transgenic mice fed a standart diet when compared with standart-diet fed control mice (data not shown). Thus, these findings suggest that GK expression in skeletal muscle induced UCP3 overexpression in this tissue.
DISCUSSION
Here we examined the effect of increased skeletal muscle glucose phosphorylation in the prevention of insulin resistance and obesity. To this end, we studied the effect of a diabetogenic high-fat diet on transgenic mice expressing GK in skeletal muscle, which showed increased glucose uptake by this tissue when fed a standard diet (18) . Glucose transport and phosphorylation in skeletal muscle are impaired in animals fed a high-fat diet (29, 30) . However, the increased intramuscular glucose 6-phosphate and glycogen concentration found in high-fat fed MLC/GK transgenic mice indicated that the increased skeletal muscle glucose uptake and utilization mediated by GK were maintained after 12 wk on this diet. Thus, these mice were normoglycemic, whereas control mice were hyperglycemic, both in fed and fasted conditions, and highly hyperinsulinemic. Moreover, the normal blood glucose levels of transgenic mice attenuated the secretory response of pancreatic ß-cells, which might also have contributed to the reduction of hyperinsulinemia observed in these mice. All this prevented insulin resistance in skeletal muscle and maintained glucose tolerance and insulin sensitivity in the whole animal. Thus, the increased glucose phosphorylation by GK expression in the skeletal muscle counteracted the diabetogenic effect of the high-fat diet. The results presented in this study are consistent with the earlier findings that MLC/GK transgenic mice increased whole body glucose tolerance and insulin sensitivity both when healthy and after streptozotocin treatment (18) . Improved glucose tolerance in the whole animal was also achieved in transgenic mice overexpressing GK in the liver (31) (32) (33) or by adenovirus-mediated GK gene transfer to rat liver (34) and skeletal muscle (19) . Moreover, transgenic mice overexpressing GK in the liver can also counteract type 1 (35) and type 2 diabetic alterations (36) . Furthermore, GK overexpression restores glucose utilization and storage in cultured hepatocytes from male Zucker diabetic fatty rats (37) . However, although GK expression in skeletal muscle improved insulin-sensitive glucose uptake, it was not sufficient to prevent elevated glucose and insulin levels associated with severe obesity in male diabetic Zucker fatty rats (20) . This was probably due to the accumulation of intracellular triacylglycerol depots in muscle, liver, and adipose tissue resulting from the lack of leptin receptor in the Zucker rat.
Besides glucose phosphorylation, the effect of increased glucose transport in skeletal muscle in the prevention of obesity and insulin resistance induced by a high-fat diet has also been studied in transgenic mice that overexpress either GLUT1 or GLUT4. Thus, overexpression of GLUT4 in transgenic mice prevents the impairment of glycemic control but not obesity caused by fat feeding (38, 39) . Similarly, high-fat fed transgenic mice overexpressing GLUT1 in skeletal muscle show improved glucose tolerance but develop insulin resistance and obesity (39) . In contrast, the increased glucose phosphorylation induced by GK expression in the skeletal muscle of the MLC/GK mice counteracted both insulin resistance and the obesity induced by the high-fat diet in control mice. Therefore, although the mechanisms by which muscle GK expression mimics a situation of insulin sensitivity are not fully understood, all of these findings are consistent with a key role of reduced glucose phosphorylation in the development of type 2 diabetes and obesity (13) .
The resistance to weight gain observed in the high-fat fed MLC/GK transgenic mice might be attributable to the improved insulin sensitivity by itself or to increased energy expenditure. Indeed, the MLC/GK transgenic mice phenotype was similar to that showed by transgenic mice, in which an increase in insulin sensitivity has been achieved through the direct genetic manipulation of regulatory proteins of insulin action (40) (41) (42) (43) . Thus, mice lacking protein tyrosine phosphatase-1B, which is involved in the negative regulation of insulin signaling, show enhanced insulin sensitivity, lower blood glucose and insulin concentrations, and improved glucose tolerance (40, 41) . Moreover, when fed a high-fat diet, these mice do not gain weight and remain insulin sensitive (40, 41) . Similarly, mice lacking the fetuin gene, which inhibits insulin-induced insulin receptor (IR) autophosphorylation and tyrosine kinase activity, show increased basal and insulin-stimulated phosphorylation of IR in liver and skeletal muscle (42) . This enhances glucose clearance and insulin sensitivity in the whole animal (42) . Furthermore, when fed a high-fat diet, fetuin knockout mice do not gain weight, show a decrease body fat, and remain insulin sensitive (42) . In addition, mice with a targeted disruption of the gene encoding the p85α regulatory subunit of phosphoinositide 3-kinase show increased insulin sensitivity and hypoglycemia due to increased glucose uptake in skeletal muscle and adipocytes (43) .
However, the reduction in body weight gain observed in the high-fat fed MLC/GK transgenic mice was accompanied by a similar food intake in controls and transgenic mice, which suggests increased energy expenditure. Similarly to transgenic mice expressing GK, transgenic mice overexpressing UCP1 or UCP3 in skeletal muscle show increased glucose uptake by skeletal muscle, improved insulin sensitivity, reduction in body weight, marked reduction in adiposity, and resistance to the obesity induced by a high-fat diet (44, 45) . These observations indicate a close relationship between insulin sensitivity and increased glucose uptake and metabolism by the skeletal muscle. Furthermore, overexpression of UCP3 induced by an increased energy substrate supply (increased glucose flux) is believed to be a mechanism in muscle cells to regulate ATP by uncoupling oxidative phosphorylation (46) . Thus, we suggest that the increased expression of UCP3 in skeletal muscle of high-fat fed transgenic mice expressing GK reflects an increase in energy expenditure, which prevents the development of obesity and insulin resistance. This is consistent with a decrease in skeletal muscle UCP3 mRNA and protein in skeletal muscle of type 2 diabetic patients (47) (48) (49) . Furthermore, there is a positive correlation between UCP3 expression in skeletal muscle and whole body insulin-mediated glucose utilization among type 2 diabetic patients (49, 50) . Decreased mitochondrial proton leak and reduced expression of UCP3 in skeletal muscle of obese diet-resistant women have also been reported (51).
In summary, our results indicate that the increase in glucose phosphorylation by GK gene expression in skeletal muscle led to increased energy expenditure that counteracted weight gain and mimicked a situation of insulin sensitivity. Therefore, our data suggest that modulation of skeletal muscle phosphorylation through the expression of the GK gene in skeletal muscle may be a therapeutic approach to improve insulin sensitivity in type 2 diabetes, obesity, and other insulin-resistant conditions. However, extensive studies of gene transfer of GK in vivo, using viral or nonviral vectors, to skeletal muscle of type 2 diabetic animal models to determine efficacy, long-term effects, safety, and feasibility must be performed before any gene therapy approach can be applied to human patients. 
